Abatacept for systemic lupus erythematosus: The outlook

Expert Opinion on Biological Therapy

Volumn 12, Issue 12, 2012, Pages 1559-1561

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Abatacept; Co stimulation; CTLA4 Ig; Lupus; Lupus nephritis; Outcome

Indexed keywords

ABATACEPT; PLACEBO; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; DRUG EFFECT; EDITORIAL; T LYMPHOCYTE;

HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 84869479561     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.721773     Document Type: Review

References (13)

1. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7
2. Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8
3. Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-16
4. Oracki SA, Tsantikos E, Quilici C, et al. CTLA4Ig alters the course of autoimmune disease development in Lyn-/- mice. J Immunol 2010;184:757-63
5. Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171:489-97
6. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent Bcell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101
7. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87
8. Tagen M, Vakkalagadda B, Thanneer N, et al. Pharmacokinetics of IV abatacept in systemic lupus erythematosus patients with active proliferative glomerulonephritis (abstract 1225). Arthritis Rheum 2011;63(10 Suppl):478
9. Furie R, Nicholls K, Cheng T-T, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo controlled phase II/III study. Arthritis Rheum 2011;63(10 Suppl):S962-3
10. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012. [Epub ahead of print]
11. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32
12. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of Lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
13. Rovin B, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26